There were 536 press releases posted in the last 24 hours and 148,411 in the last 365 days.

CJ HealthCare Corp. Therapeutics Companies And Drugs Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016 / -- CJ HealthCare Corp. Market 2016

Complete Report Details @

The, ‘CJ HealthCare Corp. - Product Pipeline Review - 2016’, provides an overview of the CJ HealthCare Corp.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CJ HealthCare Corp., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

For more information or any query mail at

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Get a Sample Report @

- The report provides a snapshot of the pipeline therapeutic landscape of CJ HealthCare Corp.
- The report provides overview of CJ HealthCare Corp. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses CJ HealthCare Corp.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features CJ HealthCare Corp.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate CJ HealthCare Corp.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for CJ HealthCare Corp.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CJ HealthCare Corp.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents – Major Key Points

List of Tables 5
List of Figures 5
CJ HealthCare Corp. Snapshot 6
CJ HealthCare Corp. Overview 6
Key Information 6
Key Facts 6
CJ HealthCare Corp. - Research and Development Overview 7
Key Therapeutic Areas 7
CJ HealthCare Corp. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
CJ HealthCare Corp. - Pipeline Products Glance 15
CJ HealthCare Corp. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
CJ HealthCare Corp. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
CJ HealthCare Corp. - Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
CJ HealthCare Corp. - Drug Profiles 22
(ezetimibe + rosuvastatin calcium) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(amlodipine besylate + candesartan cilexetil) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
(amlodipine besylate + rosuvastatin calcium + valsartan) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(atorvastatin calcium + metformin hydrochloride) XR 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
tegoprazan 26
Product Description 26


For more information or any query mail at

Get Exclusive Discount On This Report @

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here